Format

Send to

Choose Destination
Am Heart J. 2015 Oct;170(4):619-626.e2. doi: 10.1016/j.ahj.2015.06.024. Epub 2015 Jul 9.

Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease.

Author information

1
Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
2
Cardiovascular Center Aalst, Aalst, Belgium.
3
Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. Electronic address: Nico.Pijls@inter.nl.net.
4
Stanford University School of Medicine and Cancer Institute, Stanford, CA.
5
Golden Jubilee National Hospital, Glasgow, UK.
6
Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
7
Department of Cardiothoracic Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX.
8
Department of Cardiothoracic Surgery, King's College Hospital/King's Health Partners, London, UK.
9
Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA.

Abstract

Guidelines recommend coronary artery bypass graft (CABG) surgery over percutaneous coronary intervention (PCI) for the treatment of 3-vessel coronary artery disease (3-VD). The inferior results of PCI demonstrated by previous large randomized trials comparing PCI and CABG might be explained by the use of suboptimal stent technology and by the lack of fractional flow reserve (FFR) guidance of PCI.

TRIAL DESIGN:

The objective of this investigator-initiated, multicenter, randomized clinical trial is to investigate whether FFR-guided PCI with new-generation stents is noninferior to CABG in patients with 3-VD, not including the left main coronary artery. Eligible patients must have ≥50% coronary stenoses in all 3 major epicardial vessels or major side branches. Patients with a nondominant right coronary artery may be included only if the left anterior descending artery and left circumflex have ≥50% stenoses. Consecutive patients who meet all of the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 fashion to either CABG or FFR-guided PCI. Coronary artery bypass graft will be performed based on the angiogram as per clinical routine. Patients assigned to FFR-guided PCI will have FFR measured in each diseased vessel and only undergo stenting if the FFR is ≤0.80. The primary end point of the study is a composite of major adverse cardiac and cerebrovascular events, including death, myocardial infarction, repeat coronary revascularization, and stroke at 1 year. Key secondary end point will be a composite of death, myocardial infarction, and stroke at 3-year follow-up. Other secondary end points include the individual adverse events, cost-effectiveness, and quality of life at 2-year, 3-year, with up to 5-year follow-up.

CONCLUSION:

The FAME 3 study will compare in a multicenter, randomized fashion FFR-guided PCI with contemporary drug-eluting stents to CABG in patients with 3-VD.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02100722.

PMID:
26386784
DOI:
10.1016/j.ahj.2015.06.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center